Randomized phase II study of SOX B-mab versus SOX C
in the SOX+B-mab group. However, they we re significantly better when ETS was ≥20 in the SOX+C-mab group ( p=0.032 and p=0.003, respectively). Conclusions: The efficacy and safety of SOX+B-mab and SOX+C-mab f or wild-type KRAS recurrent adva